Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Mario Alberto Accardi Sells 8,322 Shares

Key Points

• Mario Alberto Accardi, an insider at Centessa Pharmaceuticals, sold 8,322 shares at $15.23 each, totaling approximately $126,744, reducing his holdings by 3.84%.
• Centessa Pharmaceuticals shares increased by 8.9% on the trading day following the insider sale, reaching a price of $16.56.
• Analysts have a consensus rating of "Moderate Buy" for Centessa Pharmaceuticals, with price targets ranging from $6.00 to $35.00.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Mario Alberto Accardi sold 8,322 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total value of $126,744.06. Following the transaction, the insider owned 208,163 shares of the company's stock, valued at approximately $3,170,322.49. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, June 24th, Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $14.00, for a total value of $210,000.00.

Centessa Pharmaceuticals Trading Down 2.1%

Shares of Centessa Pharmaceuticals stock traded down $0.36 during trading on Friday, hitting $16.81. 851,202 shares of the company were exchanged, compared to its average volume of 1,040,888. The firm has a market capitalization of $2.25 billion, a P/E ratio of -9.29 and a beta of 1.47. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.10 and a 1-year high of $19.09. The firm's fifty day moving average price is $13.90 and its 200 day moving average price is $14.42. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of CNTA. JPMorgan Chase & Co. lifted its holdings in shares of Centessa Pharmaceuticals by 40.1% during the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock valued at $3,189,000 after purchasing an additional 54,482 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Centessa Pharmaceuticals by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock valued at $1,928,000 after purchasing an additional 14,494 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after purchasing an additional 6,000 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after purchasing an additional 660 shares in the last quarter. Finally, Trexquant Investment LP lifted its holdings in shares of Centessa Pharmaceuticals by 52.8% during the 4th quarter. Trexquant Investment LP now owns 261,184 shares of the company's stock valued at $4,375,000 after purchasing an additional 90,233 shares in the last quarter. Institutional investors own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CNTA shares. Chardan Capital restated a "buy" rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday. Oppenheimer started coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective for the company. Finally, Truist Financial began coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.